Close
Smartlab Europe
Inizio Ignite

Purdue Pharma announces availability of insomnia drug

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Addressing the Boomers: How Pharma Must Adapt Drug Development for the 65+ Demographic

An aging population is reshaping medicine. Why pharma must...

GCCL, Medicover Sign MOU for Clinical Trial Services Expansion

GCCL Co., Ltd. (GCCL) and Medicover Integrated Clinical Services...

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...
- Advertisement -

Purdue Pharma has announced the availability of Intermezzo sublingual tablet CIV in 1.75mg and 3.5mg dosage strengths for insomnia characterized by middle-of-the-night awakenings followed by difficulty returning to sleep.

Intermezzo (zolpidem tartrate), which contains a bicarbonate-carbonate buffer, is available in spearmint-flavored sublingual tablets that are placed under the tongue and allowed to disintegrate completely before swallowing. The product is available on prescription in retail pharmacies in the US, the company said.

Purdue Pharma president and CEO John Stewart said: “We are confident that healthcare professionals will find Intermezzo to be a valuable therapeutic option.”

Latest stories

Related stories

Addressing the Boomers: How Pharma Must Adapt Drug Development for the 65+ Demographic

An aging population is reshaping medicine. Why pharma must...

GCCL, Medicover Sign MOU for Clinical Trial Services Expansion

GCCL Co., Ltd. (GCCL) and Medicover Integrated Clinical Services...

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...

Bristol Myers Evinova Partnership Targets AI-Led Trials

Bristol Myers Squibb has entered a global agreement with...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »